Current Immunotherapy Strategies for Rheumatoid Arthritis:The Immunoengineering and Delivery Systems  

作　　者：Chenyu Zhang Peixiang Ma An Qin Liao Wang Kerong Dai Yuanyuan Liu Jie Zhao Zuyan Lu 

机构地区：[1]School of Medicine,Shanghai University,Shanghai,China [2]Clinical and Translational Research Center for 3D Printing Technology,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China [3]Shanghai Key Laboratory of Orthopedic Implants,Department of Orthopedic Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai,China [4]Shanghai Frontiers Science Center of Degeneration and Regeneration in Skeletal System,Shanghai,China.

出　　处：《Research》2024年第3期169-189,共21页研究（英文）

基　　金：the National Science Foundation of China(82130073 and 61973206);Shanghai Leading Talents Program in 2020(110);Science and Technology Commission of Shanghai Municipality(23ZR1437600,23S31905900);Biomaterials and Regenerative Medicine Institute Cooperative Research Project,Shanghai Jiaotong University School of Medicine(2022LHA01);Science and Technology Commission of Shanghai Municipality(23S31905900);Shanghai Pujiang Program(21PJ1409200);China Postdoctoral Science Foundation(2022M722122);Shanghai Frontiers Science Center of Degen-eration and Regeneration in Skeletal System,and the Project of Biobank(YBKB202118)from Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine.

摘　　要：Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease accompanied by persistent multiarticular synovitis and cartilage degradation. The present clinical treatments are limited to disease-modifying anti-rheumatic drugs (DMARDs) and aims to relieve pain and control the inflammation of RA. Despite considerable advances in the research of RA, the employment of current clinical procedure is enormous, hindered by systemic side effect, frequent administration, tolerance from long-lasting administration, and high costs. Emerging immunoengineering-based strategies, such as multiple immune-active nanotechnologies via mechanism-based immunology approaches, have been developed to improve specific targeting and to reduce adverse reactions for RA treatments. Here, we review recent studies in immunoengineering for the treatment of RA. The prospect of future immunoengineering treatment for RA has also been discussed.

关 键 词：DRUGS RHEUMATOID treatment 

分 类 号：R593.22[医药卫生—内科学]